Saturday, November 21, 2026

Arcturus Therapeutics Stock Is 19% Down So Far On Tuesday

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Arcturus Therapeutics Stock Is 19% Down So Far On Tuesday

Arcturus Therapeutics, a San Diego-based firm committed to the development of clinical messenger RNA medicines and vaccines, is currently grappling with a noticeable downturn in the stock market. On Tuesday, the company's shares fell by a staggering 19%, reflecting a broader bearish trend. This represents the latest in a string of losses for the biotechnology company, which is now trading at 15.63% below its 52-week high.

The Pursuit of COVID-19 Therapeutics and Vaccines

Arcturus Therapeutics is primarily occupied with the development of two key candidates: ARCT-810, a therapeutic offering, and ARCT-154, a proposed vaccine. Both these initiatives are aimed at combating the ongoing COVID-19 pandemic. Notwithstanding a slumping share price, the company has reported a remarkable increase in its quarterly revenues: a year-on-year jump of 1431 percent, amounting to $281.04 million over the past year. This signifies a promising product potential.

Poor Financial Indicators

A possible explanation for Arcturus' steady market decline lies in its trailing twelve months' earnings per share (EPS) of $0.25 and a price to earnings (PE) ratio of 6.07. The figures suggest that investors are shelling out $6.07 for each dollar of the company's annual earnings, a rate that might be deemed unreasonable given the present company performance. It is worth noting, however, that Arcturus can boast of a respectable return on equity rate of 43.3%.

Market Volatility and Future Outlook

As per the stochastic oscillator, a metric used to identify oversold and overbought conditions, the stock appears overbought, potentially hinting at an impending reversal. The stock's volatility has been inconsistent, with an average weekly swing of -2.33% last week and monthly and quarterly average volatility rates of 0.444% and 2.933% respectively. This unpredictability may deter certain investors.

As the pandemic continues to shape global markets, investors should keep a close eye on Arcturus Therapeutics, especially given its ongoing role in vaccine development. Arcturus' broader stability could heavily influence its recovery, which might hinge on the success of ongoing clinical trials and ensuing earnings reports.

More news about Arcturus Therapeutics (ARCT).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 8 Aug 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.